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Objectives: In Mexico, iron deficiency anemia (IDA) is frequent and varies accord-
ing to age: children between 0 and 5 years: 23.7%, women between 15 and 44.99 
years: 15.6%, pregnant women 20.6%. Intravenous iron (IV) is a treatment option 
for IDA when patients are intolerant to oral iron or there is a need to replenish 
iron stores. The objective of this study was to estimate the relative direct health 
care costs of ferric carboxymaltose (FCM), IV iron dextran (ID), and red-blood cells 
(RBC) transfusions for patients with IDA in Mexican private hospitals. The assess-
ment has been made from the third party payer perspective represented by health 
insurances across multiple therapeutic areas (TA) (gastroenterology, gynecology, 
and surgery). MethOds: A cost-minimization analysis assuming similar efficacy 
and safety of the alternatives was conducted since the evidence of IV ID is limited 
in the selected TAs limiting our ability for indirect comparisons. Mean IV iron dose 
needed to correct IDA is estimated to be 1000 mg per patient and IV infusion time 
required is based on the Mexican SmPc for both products (FCM 15 minutes versus 
ID 6 hours). Mean cost of infusions was calculated based on daily hospitalization 
costs according to national tariffs (according to 5 private health care institutions). 
Cost savings due to IV iron-induced reduction of RBC transfusion before hip and 
knee surgery are based on published evidence (Kotze et al). Results: In all the TAs, 
the use of FCM compared to ID regarding infusion efficiency derived from reduced 
hospitalization time and IV iron-induced reduction of RBC transfusions resulted in 
substantial cost savings. Independently of the TA, mean costs savings per patient 
were $6980 Mexican pesos. cOnclusiOns: This study showed that the utilization 
of FCM could reduce costs to the health insurances at private hospitals due to 
improved administration efficiency and reduction in RBC transfusions.
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Objectives: To compare the treatment cost of anti-TNF biologics indicated simul-
taneously for the treatment of rheumatoid arthritis (RA), ankylosing spondylitis 
(AS) and psoriatic arthritis (PsA) under the Brazilian public health care system (SUS) 
perspective. MethOds: In Brazil, four anti-TNF biologics are approved for the treat-
ment of RA, AS and PsA: adalimumab (ADA), etanercept (ETA), infliximab (IFX), and 
golimumab (GOL). Published literature shows no difference in safety and efficacy 
among them; therefore, a cost-minimization analysis was performed as presented 
by Morais AD et al at ISPOR 18th Annual Meeting. Yearly treatment costs were calcu-
lated for an average patient of 70 kg, according to dose and dosing intervals defined 
in products label. Prices were gathered from an official government website, as 
the four biologics are already reimbursed by SUS: ADA, ETA and IFX for the three 
indications, and GOL for RA only. Since IFX dose is weight-dependent, deterministic 
sensitivity analysis (DSA) was conducted to determine the impact of this parameter 
on results. Results: GOL has the lowest cost of treatment across the biologics in all 
indications, at R$17,703 per patient per year. GOL treatment cost remains unchanged 
across indications or years of treatment, as loading dose is not required. For RA 
treatment, IFX has the second lowest cost of treatment at R$18,313/patient/year. 
For AS and PsA treatments, due to higher dosing of IFX, the average cost per patient 
is R$24,418, similar to the cost with ADA and ETA. Using DSA, cost of treatment 
with IFX for AS and PsA can reach up to R$30,522, assuming a patient weight of 100 
kg. cOnclusiOns: With the lowest cost of treatment, GOL is already available in 
SUS for RA treatment, and represents an important treatment option for patients 
with AS and PsA as well, with potential to reduce the cost of treatment by 27.5%.
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Objectives: To perform cost-utility analysis (CUA) of bortezomib in combina-
tion with dexamethasone (VD) or thalidomide and dexamethasone (VTD) used as 
induction treatments in ndMM patients eligible for SCT in Poland. MethOds: The 
Markov model was developed in Microsoft Excel and programmed in Visual Basic 
for Applications. The lifetime horizon and National Health Fund (NHF) perspec-
tive were taken into account. Five health states were considered: 1st line intensive 
treatment (i.e. induction, stem cell harvest, high dose chemotherapy and SCT), 2nd, 
3rd, further lines of treatment and death. Since CTD regimen (cyclophosphamide + 
thalidomide + dexamethasone) is recommended by Polish clinical guidelines as the 
most appropriate treatment in ndMM patients, both VD and VTD were compared 
to CTD. Moreover, VD and VTD were compared to VAD (vincristine + doxorubicine 
+ dexamethasone) and TD (thalidomide + dexamethasone) regimens, respectively. 
Data on clinical effectiveness regarding induction treatment were retrieved from 
three RCTs: IFM 2005-01 (VD vs VAD), PETHEMA (VTD vs TD) and Morgan 2012 (arm 
for CTD only). Data on 2nd, 3rd and further treatment lines came from APEX and 
eVOBS studies and utilities from Van Agthoven 2004. Following Polish costs were 
considered: chemotherapy, drugs administration, monitoring, maintenance therapy, 
transplant related treatment, palliative care and adverse events. The measure of 
effectiveness were quality adjusted life years (QALY). Discount rates of 5% for costs 
and 3.5% for benefits were used. Results: When compared to the main compara-
tor CTD, bortezomib-based regimens are cost-effective therapies. Results from NHF 
perspective are $31,576/QALY and $14,023/QALY, for VD and VTD respectively. The 
ICER for comparisons VD vs VAD and VTD vs TD are $25,302/QALY and $24,751/QALY. 
Obtained results are placed below the acceptability threshold in Poland ($35,278/
QALY). cOnclusiOns: Induction treatment of ndMM with bortezomib-based regi-
mens are cost-effective strategies in comparison with other available therapies in 
Poland.
transition probabilities for gabapentin were calculated from published literature 
listing gabapentin-refractory NeP patients that respond to pregabalin. Results: 
Both pregabalin and gabapentin were more effective and less costly compared to 
the placebo treatment. The quality-adjusted life years (QALYs) for SCI patients with 
NeP in the placebo, gabapentin and pregabalin groups were 0.49, 0.533, and 0.543, 
respectively. The incremental cost effectiveness ratio (ICER) for pregabalin versus 
gabapentin was $104,108 (US$, 2012). The model suggests that a modest change (5% 
reduction) in indirect costs with pregabalin treatment reduces the ICER to $31,096. 
One-way sensitivity analyses show that the model is most sensitive to pregabalin’s 
efficacy at alleviating NeP in gabapentin-refractory SCI patients, and utility scores 
for the four NeP-severity health states in SCI patients. The model also shows that 
changes in the direct and indirect costs associated with the four health states are 
inconsequential. cOnclusiOns: Pregabalin is cost-effective as a first-line treat-
ment for SCI-associated NeP in the United States provided that there is a pregabalin 
treatment-specific reduction in indirect costs.
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Objectives: Methylmalonic academia (MMA) and propionic academia (PA) are 
rare inborn errors of metabolism that cause significant morbidity and are associ-
ated with early mortality among patients. The mainstay of the long-term medi-
cal management relies on a lifelong protein-restricted and high-energy diet. Liver 
transplantation is a relatively infrequently used alternative therapy that corrects 
the metabolic errors and potentially improves survival and quality of life. The objec-
tive of this study is to estimate the incremental clinical and economic outcomes 
associated with liver transplantation vs. nutritional support among patients with 
MMA and PA. MethOds: We constructed a three health state Markov model using 
data derived from the United Network for Organ Sharing (UNOS) database, meta-
analyses, cohort studies, narrative reviews, and expert opinions when necessary. 
Societal and payer perspectives were considered. Lifetime direct and indirect costs, 
life expectancies, and quality-adjusted life-years (QALYs) were estimated based 
on one-year model cycles for hypothetical cohorts of newborns with MMA and PA, 
respectively. We conducted a series of one-way sensitivity analyses to assess the 
impact of parameter assumptions on the result. Scenario analyses were performed, 
including a worst-case scenario setting all parameters to favor nutritional sup-
port. Results: In the base case analysis liver transplantation was the dominant 
strategy, saving $1,594,995 in lifetime societal costs and generating 8 more QALYs 
compared to nutritional support. Liver transplantation remained dominant from 
the payer perspective, saving $1,171,978 throughout lifetime. In one-way sensitiv-
ity analyses we found that discount rate and annual mortality rates are the most 
influential parameters on costs and QALYs respectively. In the worse-case scenario, 
liver transplantation still produced lower costs but lower QALYs (-12.1) compared 
to the nutritional support group. cOnclusiOns: Liver transplantation appears to 
be a cost-effective treatment alternative compared to nutritional support in MMA 
and PA patients. Future research is needed on the long-term survival and quality 
of life in these patient populations.
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Objectives: To compare the treatment cost of anti-TNF biologics indicated simul-
taneously for the treatment of rheumatoid arthritis (RA), ankylosing spondylitis 
(AS) and psoriatic arthritis (PsA) under the Brazilian private health care system 
perspective. MethOds: In Brazil, four anti-TNF biologics are approved for the treat-
ment of RA, AS and PsA: adalimumab (ADA), etanercept (ETA), infliximab (IFX), and 
golimumab (GOL). Published literature shows no difference in safety and efficacy 
among them; therefore, a cost-minimization analysis was performed as presented 
by Morais AD et al at ISPOR 18th Annual Meeting. Yearly treatment costs were cal-
culated for an average patient of 70 kg, according to dose and dosing intervals 
defined in products label. Prices were gathered from the official price list. Since IFX 
dose is weight-dependent, deterministic sensitivity analysis (DSA) was conducted 
to determine the impact of this parameter on results. Results: GOL has the low-
est cost of treatment across the biologics in all indications, at R$41,555 per patient 
per year. GOL treatment cost remains unchanged across indications or years of 
treatment, as loading dose is not required. For RA treatment, IFX has the second 
lowest cost of treatment at R$60,720/patient/year. For AS and PsA treatments, due 
to higher dosing of IFX, the average cost per patient is R$80,960, similar to the cost 
with ADA and 8.8% above ETA. Using DSA, cost of treatment with IFX for AS and PsA 
can reach up to R$101,199, assuming a patient weight of 100 kg. cOnclusiOns: 
Treatment with GOL compared to the other anti-TNFs may bring important savings 
to the private payers (HMOs), not only in RA, but also in AS and PsA, with potential to 
reduce the cost of treatment by 48.7%, and so allowing a higher number of patients 
to be treated at same budget level.
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